Short-Term Exposure to Violet Light Emitted from Eyeglass Frames in Myopic Children: A Randomized Pilot Clinical Trial.
Hidemasa ToriiKiwako MoriTakashi OkanoShinichiro KondoHao-Yung YangErisa YotsukuraAkiko HanyudaMamoru OgawaKazuno NegishiToshihide KuriharaMasayuki OhtaPublished in: Journal of clinical medicine (2022)
Violet light (VL), 360-400 nm wavelength, is contained in the sunlight and is an effective element for myopia suppression. This study is to investigate the safety and efficacy of novel eyeglasses that emit VL from the frames. This is a double-masked, randomized, pilot clinical trial conducted in a clinic in Japan. Forty-three children with myopia were enrolled. Participants were randomly assigned to two groups, wearing VL-emitting eyeglass frames (VLf) that emitted VL of 310 μW/cm 2 (VLf group, n = 22) or pseudo-placebo eyeglass frames with a minimal emission of VL (<10 μW/cm 2 ) (control group, n = 21). The exposure time was 3 h per day. The primary outcomes were visual acuity, tear film break-up time, corneal endothelial cell density, and the slit-lamp/fundus examinations. The secondary outcome was the 6-month changes in the axial lengths and cycloplegic refractions. Forty-one (95%) participants were included; twenty-one in the VLf group and twenty in the control group. No significant differences were seen in any safety evaluation. Significant changes were seen in axial elongation, choroidal thickness, and cycloplegic refractions in the subgroup analysis of 8- to 10-year-old children ( p < 0.05), but otherwise no significant differences were seen. The VLf showed short-term safety and effectiveness against myopia progression.
Keyphrases
- clinical trial
- double blind
- phase iii
- study protocol
- open label
- optical coherence tomography
- phase ii
- young adults
- randomized controlled trial
- placebo controlled
- optic nerve
- endothelial cells
- systematic review
- primary care
- adipose tissue
- type diabetes
- diabetic retinopathy
- metabolic syndrome
- insulin resistance
- room temperature
- gold nanoparticles
- reduced graphene oxide